市場調查報告書
商品編碼
1498628
生物分析測試服務市場規模、佔有率、成長分析、按分子、按測試、按工作流程、按應用、按最終用戶、按地區 - 行業預測,2024-2031 年Bioanalytical Testing Services Market Size, Share, Growth Analysis, By Molecule, By Test, By Workflow, By Application, By End User, By Region - Industry Forecast 2024-2031 |
2022年生物分析測試服務的市場規模將為24.2億美元,預測期內(2024-2031年)複合年成長率為15%,從2023年的27.8億美元增加到2031年的85億美元。成長到美國1000萬美元。
生物分析測試服務市場包括向製藥和生技藥品。這些服務包括測量生物體液和組織(例如血液、尿液和組織)中的藥物、代謝物和生物標記濃度,對於藥物開發和監管核准至關重要。例如,藥明康德是生物分析自動化的早期採用者,將生產力提高了 400%。該市場由 CRO 和其他服務供應商組成,旨在提供高效、準確的測試來支持藥物開發。開發和核准新藥的需求是成長動力,但高成本和缺乏標準化方法是主要挑戰。
Bioanalytical Testing Services Market size was valued at USD 2.42 Billion in 2022 and is poised to grow from USD 2.78 Billion in 2023 to USD 8.51 Billion by 2031, at a CAGR of 15 % during the forecast period (2024-2031).
The bioanalytical testing services market encompasses analytical services provided to pharmaceutical and biotech companies to assess the safety and efficacy of drugs and biologics in humans. These services, which include measuring drug, metabolite, and biomarker concentrations in biological fluids and tissues such as blood, urine, and tissue, are crucial for drug development and regulatory approval. For example, WuXi AppTec's early adoption of bioanalytical automation led to a 400% productivity increase. The market consists of CROs and other service providers, aiming to deliver efficient and accurate testing to support drug development. Growth is driven by the need for new drug development and approval, but high costs and lack of standardized methods pose significant challenges.
Top-down and bottom-up approaches were used to estimate and validate the size of the Bioanalytical Testing Services Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Bioanalytical Testing Services Market Segmental Analysis
Bioanalytical Testing Services Market is segmented based on Molecule, Test, Workflow, Application, End User and region. By molecule, the market is segmented into small molecules and large molecules. By test, the market is segmented into ADME, Pharmacokinetics, Pharmacodynamics, Bioavailability, Bioequivalence, and Others. By Workflow, the market is segmented into Sample Preparation (Protein Precipitation, Liquid-Liquid Extraction, Solid Phase Extraction), Sample Analysis (Hyphenated technique, Chromatographic technique, Electrophoresis, Ligand Binding Assay, Mass Spectrometry, Nuclear Magnetic Resonance). By application, the market is segmented into Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology, and others. By end users, the market is segmented into Pharmaceutical and Biopharmaceutical Companies, Contract Development and Manufacturing Organizations, and Contract Research Organizations. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Bioanalytical Testing Services Market
The increasing demand for personalized medicines is significantly boosting the bioanalytical testing services sector, which is crucial for developing and testing these tailored treatments. Bioanalytical testing is essential in assessing drug efficacy for individual patients, ensuring the selection of the most suitable treatment plans. For example, the global surge in cancer cases has driven the need for self-administered, forward-looking drugs, making this a highly profitable market. This focus on personalized cancer therapies has, in turn, accelerated the growth of the bioanalytical testing market by improving the effectiveness of cancer treatments through more precise and patient-specific drug evaluation.
Restraints in the Bioanalytical Testing Services Market
The bioanalytical testing market faces significant growth constraints due to a shortage of skilled personnel capable of managing advanced equipment requirements. This challenge is underscored by the projected 13% increase in demand for medical laboratory technicians between 2016 and 2026, highlighting a critical gap in workforce supply. Without sufficient skilled technicians, the adoption of new technologies and processes may be hindered, thereby limiting market expansion. As the industry evolves, this shortfall in expertise could pose substantial barriers, restricting the ability to fully leverage technological advancements and meet the growing needs of the bioanalytical testing sector.
Market Trends of the Bioanalytical Testing Services Market
Pharmaceutical companies are increasingly turning to third-party service providers for bioanalytical testing to cut costs, boost efficiency, and concentrate on their primary areas of expertise. This outsourcing trend is anticipated to grow in the foreseeable future. By partnering with specialized external firms, pharmaceutical companies can leverage advanced technologies and expert knowledge without the burden of maintaining extensive in-house laboratories. This strategic shift allows them to streamline operations, enhance productivity, and allocate more resources to drug development and innovation, thereby accelerating time-to-market for new therapies and responding more swiftly to evolving industry demands and regulatory requirements.